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Abstract
Background: The availability of serum collections from the Women’s Health Initiative (WHI)
conjugated equine estrogens (CEE) randomized controlled trial provides an opportunity to test
the potential of in-depth quantitative proteomics to uncover changes in the serum proteome
related to CEE and to assess their relevance to trial findings, including elevations in the risk of
stroke and venous thromboembolism and a reduction in fractures.
Methods: Five independent large scale quantitative proteomics analyses were performed, each
comparing a set of pooled serum samples collected from 10 subjects, 1 year following initiation of
CEE at 0.625 mg/d, relative to their baseline pool. A subset of proteins that exhibited increased
levels with CEE by quantitative proteomics was selected for validation studies.
Results: Of 611 proteins quantified based on differential stable isotope labeling, the levels of 116
(19%) were changed after 1 year of CEE (nominal P < 0.05), while 64 of these had estimated false
discovery rates <0.05. Most of the changed proteins were not previously known to be affected by
CEE and had relevance to processes that included coagulation, metabolism, osteogenesis,
inflammation, and blood pressure maintenance. To validate quantitative proteomic data, 14
proteins were selected for ELISA. Findings for ten - IGF1, IGFBP4, IGFBP1, IGFBP2, F10, AHSG,
GC, CP, MMP2, and PROZ - were confirmed in the initial set of 50 subjects and further validated
in an independent set of 50 additional subjects who received CEE.
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Background
Estrogens exert effects on target genes in various tissues
through complex processes [1]. Given the widespread use of
conjugated equine estrogens (CEE) and other estrogens for
menopausal symptoms, the issue of overall health benefits
and risks associated with CEE has been a major research
focus. For example, recommendations for use of estrogen for
prevention of coronary heart disease (CHD) were based on
epidemiologic, animal, and laboratory data [2,3]. However,
the Women’s Health Initiative (WHI) randomized, placebo
controlled trial of 0.625 mg/d continuous CEE among
10,739 women who were post-hysterectomy did not provide
evidence of benefit for CHD, and health benefits and risks
appeared to be approximately balanced [4]. It has been
suggested that women who started CEE earlier after meno-
pause could be at lower risk of CHD, but not stroke, than
women who initiated hormone therapy more distant from
the menopause [5-8]. Demonstrated benefits of CEE include
improvement of vasomotor symptoms [9] and prevention of
osteoporotic fractures, in particular reduction in hip
fractures [10,11]. Adverse effects observed in the WHI trial
include increased incidence of venous thromboembolism
and stroke [4,12,13].
Recent studies, including the WHI trials, have shown that
estrogen therapy (ET) induced changes in several proteins
and metabolites, including decreases in low-density lipo-
protein cholesterol and increases in high-density lipoprotein
cholesterol and triglycerides; decreases in fasting glucose,
insulin, and homocysteine; increases in C-reactive protein,
matrix metalloproteinase-9 and plasmin-antiplasmin complex;
and decreases in E-selectin and plasmin activator inhibitor
[14]. Other studies have documented increases in angio-
tensinogen and its product angiotensin II, a potent vaso-
constrictor, and suppression of active renin with post-
menopausal ET [15,16]. There is also some evidence of an
effect on insulin-like growth factor (IGF) and IGF binding
proteins (IGFBPs) in postmenopausal women [17,18]. Given
these diverse effects, an unbiased comprehensive profiling of
serum to assess the effect of CEE is warranted. However,
such comprehensive quantitative proteomic profiling in the
context of a clinical trial has not been done previously. Thus,
it was of interest to determine whether proteomic profiling
would uncover protein changes that have relevance to WHI
CEE trial findings.
We have applied an intact protein analysis system (IPAS)
approach that allows identification of proteins over seven
orders of magnitude of abundance to determine the effect of
oral CEE on the serum proteome [19-22]. A prior proteomic
study of hormone therapy-relevant samples [23] relied on a
fingerprinting approach with limited sensitivity and without
protein identification. In this study we present a systematic
global proteome analysis of sera obtained at baseline and
after 1 year of oral ET from 50 postmenopausal women. We
have validated quantitative proteomic data for a subset of
proteins by enzyme-linked immunosorbent assay (ELISA)
with sera from the initial set of 50 subjects and with sera
from an independent set of 50 randomly selected subjects
who adhered to CEE and that were obtained at baseline and
after 1 year of oral ET.
Methods
Study design
Use of human samples was approved by the Fred
Hutchinson Cancer Research Center Institutional Review
Board. For the discovery phase of this study, 50 subjects
were randomly selected from women in the WHI trial who
received and adhered to oral CEE 0.625 mg daily over the
first year from randomization, and who did not experience a
major clinical outcome during trial follow-up. This popu-
lation is a substudy of the WHI CEE trial, which is composed
of 10,739 women, 5,310 in the active CEE arm and 5,429 in
the placebo arm. These women had each undergone hys-
terectomy, and most had never received hormone therapy
prior to trial enrollment. Some were prior postmenopausal
hormone therapy users who had stopped hormone therapy
some months or years prior to trial enrollment. Rarely,
subjects were current hormone therapy users at baseline
screening and these subjects were required to undergo a 3
month ‘wash-out’ period of no hormone therapy use prior to
randomization. Sera were collected before and after 1 year
of CEE in 7 ml royal blue-stoppered serum tubes for trace
elements, no additive, silicone coated (BD 367737), and
frozen at -80°C until proteomic analysis. All subjects in
this substudy were adherent to study medication (defined
as taking >80% of study medication per protocol)
throughout the first year from randomization. Sera from a
second subgroup (n = 50) of women from the active CEE
arm of the CEE trial who met the same selection criteria
were included in an independent sample ELISA validation
phase of this study.
Sample preparation
Sera samples at baseline and 1 year after ET (50 women
total) were divided in 5 experiments. For each experiment
30 µl aliquots of sera from 10 women at baseline, and
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Conclusions: CEE affected a substantial fraction of the serum proteome, including proteins with
relevance to findings from the WHI CEE trial related to cardiovascular disease and fracture.
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10 women 1 year after ET were pooled. Baseline and treated
pools were then individually immunodepleted of the top six
most abundant proteins (albumin, IgG, IgA, transferrin,
haptoglobin and antitrypsin) using a Hu-6 column
(4.6 × 250 mm; Agilent, Wilmington, DE, USA). Briefly,
columns were equilibrated with buffer A at 0.5 ml/minutes
for 13 minutes and aliquots of 75 µl of the pooled sera were
injected after filtration through a 0.22 µm syringe filter. The
flow-through fractions were collected for 10 minutes at a
flow rate of buffer A of 0.5 ml/minute, combined and stored
at -80ºC until use. The column bound material was
recovered by elution for 8 minutes with buffer B at
1 ml/minute. Subsequently, immunodepleted samples were
concentrated using Centricon YM-3 devices (Millipore,
Billerica, MA, USA) and re-diluted in 8 M urea, 30 mM Tris
pH 8.5, 0.5% OG (octyl-beta-d-glucopyranoside; Roche
Diagnostics, Indianapolis, IN, USA). Samples were reduced
with DTT in 50 µl of 2 M Tris-HCl pH 8.5 (0.66 mg DTT/mg
protein), and isotopic labeling of intact proteins in cysteine
residues were performed with acrylamide. Baseline pools
received the light acrylamide isotope (C12 acrylamide;
>99.5% purity; Sigma-Aldrich (Fluka), St. Louis, MO, USA),
and their corresponding 1 year ET pools received the heavy
1,2,3-C13-acrylamide isotope (C13 acrylamide; >98% purity;
Cambridge Isotope Laboratories, Andover, MA, USA).
Alkylation with acrylamide was performed for 1 h at room
temperature by adding to the protein solution the appro-
priate quantity of C12-acrylamide or C13-acrylamide per
milligram protein, diluted in a small volume of 2 M Tris-HCl
pH 8.5 [19]. For each of the five experiments, the pool of
baseline (C12) and estrogen-treated (C13) samples was then
mixed together for further analysis.
Protein fractionation
The two-dimensional protein fractionation has been per-
formed based on the previously described IPAS approach
[20,22,24]. Briefly, after isotopic labeling and mixing of the
two pools, the sample was diluted to 10 ml with 20 mM Tris
in 6% isopropanol, 4 M urea pH 8.5 and immediately injected
in a Mono-Q 10/100 column (Amersham Biosciences, Pis-
cataway, NJ, USA) for the anion-exchange chromatography,
the first dimension of the protein fractionation. The buffer
system consisted of solvent A (20 mM Tris in 6% isopro-
panol, 4 M urea pH 8.5) and solvent B (20 mM Tris in 6%
isopropanol, 4 M urea, 1 M NaCl pH 8.5). The separation
was performed at 4.0 ml/minutes in a gradient of 0-35%
solvent B in 44 minutes; 35-50% solvent B in 3 minutes;
50-100% solvent B in 5 minutes; and 100% solvent B for an
additional 5 minutes. A total of 12 pools were collected from
the anion exchange chromatography. The 12 pools were then
subjected to a second dimension of separation by reversed-
phase chromatography. The reversed-phase fractionation
was carried out with a Poros R2 column (4.6 × 50 mm;
Applied Biosystems, Foster City, CA, USA) using trifluoro-
acetic acid/acetonitrile as buffer system (solvent A, 95%
H2O, 5% acetonitrile, 0.1% trifluoro-acetic acid; solvent B,
90% acetonitrile, 10% H2O, 0.1% trifluoro-acetic acid) at
2.7 ml/minutes. The gradient used was 5% solvent A until
absorbance reached baseline (desalting step) and then
5-50% solvent B in 18 minutes; 50-80% solvent B in 7 minutes
and 80-95% solvent B in 2 minutes. Sixty fractions of 900 µl
were collected during the run, corresponding to a total of
720 fractions for each experiment. Aliquots of 200 µl of each
fraction, corresponding to approximately 20 µg of protein,
were separated for mass-spectrometry shotgun analysis.
Mass spectrometry analysis
For protein identification we performed in-solution trypsin
digestion with the lyophilized aliquots of the 720 individual
fractions. Individual digested fractions 4 to 60 from each
reversed-phase run were pooled in 11 pools, corresponding
to a total of 132 fractions for analysis from each experiment.
Tryptic peptides were analyzed by a LTQ-FT mass spectro-
meter (Thermo-Electron, Waltham, MA USA) coupled to a
nano-Aquity nanoflow chromatography system (Waters,
Milford, MA, USA). The liquid chromatography separation
was performed in a 25 cm column (Picofrit 75 µm ID; New
Objective, Woburn, MA, USA), in-house-packed with
MagicC18 (Michrom Bioresources, Auburn, CA, USA) resin
using a 90 minutes linear gradient from 5-40% of aceto-
nitrile in 0.1% formic acid at 250 nl/minute. The spectra
were acquired in a data-dependent mode in a m/z range of
400 to 1,800, and selection of the 5 most abundant +2 or +3
ions of each mass spectrometry (MS) spectrum for MS/MS
analysis. Mass spectrometer parameters were: capillary
voltage of 2.1 KV; capillary temperature of 200ºC; resolution
of 100,000; and FT target value of 1,000,000.
Protein identification
The acquired LC-MS/MS data were automatically processed
by the Computational Proteomics Analysis System (CPAS)
[25]. For the identification of proteins with a false discovery
rate (FDR) <5%, database searches were performed using
X!Tandem against the human IPI (International Protein
Index) database v.3.13 using tryptic search [25]. Cysteine
alkylation with the light form of acrylamide was set as a fixed
modification and with the heavy form of acrylamide
(+3.01884) as a variable modification. The database search
results were then analyzed by PeptideProphet [26] and
ProteinProphet [27] programs. Our high confidence list of
identifications retained proteins with ProteinProphet scores
≥0.95 (5% error rate) and two or more peptides per protein.
Quantitative analysis of protein levels
Quantitative ratios of proteins comparing 1-year to baseline
samples were obtained by differential labeling of peptides
containing cysteine with acrylamide isotopes (heavy or
light). Quantitative information was extracted using a script
designated ‘Q3ProteinRatioParser’ that was developed in-
house to obtain the relative quantification for each pair of
peptides identified by MS/MS that contains cysteine
residues [19]. Only peptides with a minimum PeptideProphet
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score of 0.75, and mass deviation <20 ppm were considered
for quantification. Ratios of heavy-to-light acrylamide-
labeled peptides were plotted on a histogram (log2 scale)
and the median of the distribution was centered at zero. This
normalization approach was chosen since the great majority
of proteins were not expected to be deregulated in 1-year ET
compared to baseline samples. All normalized peptide ratios
for a specific protein were averaged to compute an overall
protein ratio. Proteins for which only peptides labeled with
the heavy form of acrylamide were detected were included in
the final list of proteins with quantitative information pre-
sented as ‘1-year ET only’. All peptide and protein ratios
were calculated on a logarithmic scale. Statistical signifi-
cance of the protein quantitative information was obtained
via two procedures: for those proteins with multiple peptides
quantified, a P-value for the mean log-ratio, which has mean
zero under the null hypothesis, was calculated using one-
sample t-test; and for proteins with a single paired MS event,
the probability for the ratio was extrapolated from the
distribution of ratios in a baseline-baseline experiment
whereby the same sample was labeled with heavy and light
acrylamide. The raw data and summary list of identified and
quantified proteins are available through the Computational
Proteomics Analysis System upon request.
Statistical comparison of five IPAS proteomics analyses
Protein ratios were analyzed to identify proteins whose
average ratio (1 year of CEE/baseline), averaged over the five
proteomic experiments, differed from zero on a log2 scale.
All analyses were performed using the statistical package R
[28]. Protein log-ratios were normalized across experiments
by a median location shift to ensure the distributions of
proteins for each IPAS experiment were centered at zero.
Protein log-ratios were standardized by forming a sample
variance from the (up to five) log-ratios for each protein, and
adding a corresponding sample variance from a corres-
ponding set of (up to five) log-ratios from a completely
analogous set of five proteomic experiments from the WHI
estrogen plus progestin trial. Statistical testing was
performed by using a weighted moderated t-statistic [29]
implemented in the R package LIMMA [30]. A weighted
average ratio was calculated for each protein by weighting
the (up to five) log-ratios by the number of quantified
peptides for each protein and a matrix of weights was
included in the linear model. Benjamini and Hochberg’s
method for controlling the FDR was used to compute
adjusted P-values [31].
To improve our estimate of the posterior standard deviation
used in the moderated t-statistics, protein ratios from an
additional five IPAS experiments that compare estrogen plus
progestin and whose quantification followed exactly the
same protocol were also included in the linear model.
Specifically, average ratios were calculated by fitting a linear
model where the design matrix consisted of two dummy
variables indicating estrogen or estrogen plus progestin use.
All results in this manuscript are based on inferences for the
dummy variable of estrogen use (that is, the average ratio for
ET use). Including the estrogen plus progestin data does not
affect the estimated values of the ET ratios, but does increase
the degrees of freedom and consequently increases power.
Networks analysis
For network analysis, the unfiltered list of gene names of
proteins, and their ratios and P-values from all five IPAS
experiments were uploaded into the MetaCore analytical
suite version 4.7 (GeneGO, Inc., St. Joseph, MI, USA), and
analysis was performed as described previously [32].
ELISA-based validation
Measurements were performed on the same sera from the
50 women utilized for proteomic analysis using ELISAs
according to the manufacturer’s protocols: human IGFBP1,
IGFBP2, IGFBP4, and IGFBP6 (R&D Systems, Minneapolis,
MN, USA); IGF1 (Diagnostic Systems Laboratories, Webster,
TX, USA); factor IX (F9), factor X (F10), and PROZ (protein
Z, vitamin K-dependent plasma glycoprotein) (Hyphen
Biomed, Neuville-Sur-Oise, France); ceruloplasmin (US
Biological, Swampscott, MA, USA); vitamin D binding protein
(Alpco Diagnostics, Salem, NH, USA); fetuin-A (AHSG)
(Biovendor, Candler, NC, USA); vitronectin (Innovative
Research, Novi, MI, USA); KNG1 (Affinity Biologicals,
Ancaster, ON, Canada); MMP2 (Calbiochem, Gibbstown,
NJ, USA). Individual serum samples and standards were run
in duplicate and absorbance measured using a SpectraMax
Plus 384 and results calculated with SoftMax Pro v4.7.1
(Molecular Devices, Sunnyvale, CA, USA). P-values and
testing whether there was a significant change from baseline
to year 1 for individual proteins were computed using the
non-parametric t-test on the log2 scale. For a particular
protein, validity of IPAS results was gauged by comparing
means (95% confidence intervals) of protein ratios to results
from standard ELISA kits. The t-statistic and moderated
t-statistic were used to calculate 95% confidence intervals for
ELISA and IPAS data. For comparison of discovery and
validation findings we also report Pearson’s correlation
coefficients for log-ratios.
Results
Proteomic analysis of sera from study subjects
Some characteristics at baseline of the 50 subjects included
in the discovery phase are summarized in Table 1. There
were no statistically significant differences in any baseline
characteristics noted between pools. The average age of the
subjects was 61.4 ± 7.9 years (mean ± standard deviation).
There were 2,576,869 tandem mass spectra with >0.05
PeptideProphet score acquired in these experiments (Table 2);
1,760,094 spectra yielded proteins identified with a <5%
error rate. To our knowledge, this serum protein dataset is
the largest obtained from a human observational study or
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clinical trial to date. This remarkable size of the serum
protein dataset is a result of the extensive fractionation and
large number of mass spectra collected in these experiments.
The number of proteins identified and quantified showed
some variation between experiments (16% coefficient of
variation for number of quantified proteins), which may be
related to sample processing and MS sampling. However,
this variation is not expected to affect quantitative ratios, as
each experiment consisted of combined baseline and post-
therapy sera that were differentially isotopically labeled
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Table 1
Overview of subject characteristics (n = 50)
N % N %
Age group at screening, years
50-59 25 50.0
60-69 13 26.0
70-79 12 24.0
Ethnicity
White 42 84.0
Black 5 10.0
Hispanic 3 6.0
Hormone replacement therapy use
Never used 26 52.0
Past user 19 38.0
Current user 5 10.0
Hormone replacement therapy duration, years
<5 16 66.7
5 to <10 3 12.5
10+ 5 20.8
Body mass index (BMI), kg/m2
<25 6 12.2
25 to <30 18 36.7
≥30 25 51.0
BMI at year 1
<25 3 6.1
25 to <30 21 42.9
≥30 25 51.0
Smoking
Never smoked 29 58.0
Past smoker 19 38.0
Current smoker 2 4.0
Parity
Never pregnant/no term pregnancy 4 8.0
≥1 term pregnancy 46 92.0
Age at first birth, years
<20 15 34.1
20-29 27 61.4
30+ 2 4.5
Age at hysterectomy, years
<40 19 38.0
40-49 18 36.0
50-54 6 12.0
55+ 7 14.0
Prior bilateral oophorectomy
No 33 71.7
Yes 13 28.3
Treated diabetes
No 43 86.0
Yes 7 14.0
Treated for hypertension or blood pressure ≥140/90 mmHg
No 29 63.0
Yes 17 37.0
History of high cholesterol requiring pills
No 42 95.5
Yes 2 4.5
Statin use at baseline
No 48 96.0
Yes 2 4.0
Aspirin (≥80 mg) use at baseline
No 42 84.0
Yes 8 16.0
History of myocardial infarction
No 50 100.0
History of angina
No 47 94.0
Yes 3 6.0
History of coronary artery bypass graft/percutaneous transluminal
coronary angioplasty
No 47 100.0
History of stroke
No 50 100.0
History of deep vein thrombosis or pulmonary embolism
No 50 100.0
Family history of breast cancer (female)
No 41 85.4
Yes 7 14.6
History of fracture on/after age 55
No 31 96.9
Yes 1 3.1
Gail Model five year risk of breast cancer
<1 10 20.0
1 to <2 34 68.0
2 to <5 6 12.0
Number of falls in last 12 months
None 30 69.8
1 7 16.3
2 6 14.0
prior to mixing. Labeling efficiency was evaluated and the
results are shown in Figure 1. The log-ratio histograms were
all approximately Gaussian shaped.
Changes observed at 1 year following ET relative to baseline
A list of weighted, quantified protein products of 611 distinct
genes resulted from the serum proteomic analysis (Additional
data file 1), after filtering protein identifications to remove
proteins without associated gene name (hypothetical proteins)
and false identifications based on manual verification of
mass spectra. The log2 ratios of protein levels (1 year
CEE/baseline), derived from the isotopic labeling of cysteine
residues, and their P-values is provided as volcano plots
(Figure 2a). We found that 116 of the 611 proteins quantified
in the serum met a nominal 0.05 significance level criterion
for change after 1 year of CEE, compared to about 31 ex-
pected by chance. A similar view was obtained when
adjusted P-values (FDR <0.05) were considered (Figure 2b).
We found that 64 of the 611 proteins quantified (10.5%) in
the serum had estimated FDRs of P < 0.05 for change from
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Table 2
Overview of proteomic analysis characteristics
Number of tandem mass Number of spectra that Number of unique 
Experiment spectra acquired yielded protein identifications with <5% error rate proteins quantified
1 414,895 293,466 543
2 584,525 403,189 574
3 524,366 355,411 575
4 573,327 381,057 530
5 479,756 326,971 370
Total 2,576,869 1,760,094 1,056
Figure 1
Distribution of ratios for quantified peptides for the five IPAS experiments. A histogram of 1-year CEE/baseline (log2) ratios as determined from heavy-
to-light isotopic labeling with acrylamide are shown for each IPAS experiment. The median of the distribution was centered at zero for normalization.
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baseline to 1 year from randomization (Additional data
file 2), while a strongly overlapping set of 64 proteins had
nominal P < 0.05 and also had estimated log-ratios >1.20 or
<1/1.20 (Additional data file 3). A network analysis of the 64
proteins with statistically significant changes relative to all
quantified proteins and with an FDR <0.05 (MetaCore
version 4.7) [32-35] yielded a significant enrichment in five
networks: blood coagulation, kallikrein-kinin system, cell
adhesion-platelet-endothelium-leukocyte interactions, comple-
ment system, and ossification (Table 3). We further classified
these 64 proteins in relation to the known biological processes
they are involved in through a search of the Gene Ontology
(GO) database (Table 4). A search of the literature yielded
prior associations with ET for 13 of the 64 proteins
(ceruloplasmin (CP), plasminogen (PLG), tissue factor path-
way inhibitor (TFPI), sex hormone binding globulin (SHBG),
IGFBP1, IBFBP4, apolipoprotein A-II (APOA2), vitamin D
binding protein (GC), apolipoprotein D (APOD), IGF1, AHSG,
lactotransferrin (LTF), angiotensinogen (AGT); Table 4).
Thus, novel associations were observed for 41 proteins. These
proteins are associated primarily with blood coagulation,
metabolism regulation, complement/inflammation/innate
immunity, ossification, cellular growth, cell-cell/cell-matrix
interactions, vessel morphogenesis/angiogenesis and blood
pressure maintenance processes.
A critical step in estrogen effect on gene expression is recog-
nition of the estrogen response elements (EREs) via estrogen
receptors. For the differentially expressed proteins, we
checked for the presence of conserved (between mouse and
human) EREs in their corresponding genes. The sequence
match was performed against a publicly available ERE
database [36]. Four proteins - AGT, galectin-1 (LGALS1), LTF,
and trefoil factor 3 (TFF3) - found to be significantly
elevated with CEE in our study, had conserved EREs
upstream of the coding region. None of the down-regulated
proteins had conserved EREs upstream of the coding regions
of their genes. However, one down-regulated protein (matrix
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Figure 2
Volcano plots. (a) For nominal P-values. Relationship between the 1-year ET/baseline log2 ratios and their P-values. (b) For FDR adjusted P-values.
Relationship between the 1 year ET/baseline log2 ratios and their FDR adjusted P-values.
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metalloproteinase 2 (MMP2)) had an ERE in the down-
stream region of its corresponding gene.
Validation of a set of proteins up-regulated with ET
We sought to validate proteomic data by ELISA analysis of
individual non-pooled sera from the same subjects in the
study. Proteins were selected for assay among the set of 64
proteins meeting statistical criteria for change following
CEE, based on availability of a pair of antibodies with the
requisite specificity for ELISA-based validation. Thus, assays
were available for IGF1, IGFBP4, IGFBP1, IGFBP6, F9, F10,
AHSG, vitronectin (VTN), GC, CP, MMP2, kininogen (KNG1),
and PROZ. In addition, IGFBP2 was tested as a negative
control. SHBG was separately analyzed in a set of 50 women
in the trial, who had similar characteristics to those in the
training set. High-density lipoprotein and low-density lipo-
protein were previously tested and, therefore, were not
subjected to additional validation in our study [6]. Figure 3
presents the data at baseline and 1 year for each protein. The
correlation between IPAS proteomic log-ratios and ELISA
log-ratios was strong (correlation = 0.83 without SHBG and
0.86 with SHGB; Figure 4). We obtained a correlation of
0.85 between spectral counts (number of tandem mass
spectrometry (MS2) events/protein) and the known serum
concentrations of more than 80 proteins (Figure 5a). The
measured abundance range of the proteins subjected to
ELISA (Figure 5b) is indicative of the depth of proteomic
analysis in this study, which was achieved through extensive
fractionation of intact proteins and reliance on high-reso-
lution MS, spanning seven logs of protein abundance.
However, low abundance proteins are somewhat under-sam-
pled, given that proteins quantified in more than two proteo-
mic experiments only spanned some four logs of protein
abundance.
Validation studies in an independent set of sera
We further analyzed an additional, independent validation
set of 50 non-overlapping randomly selected women, who
adhered to CEE over the first year of randomization in the
CEE trial, for IGF1, IGFBP4, IGFBP1, F10, AHSG, GC, CP,
MMP2, and PROZ and for IGFBP2 as a negative control
(Figure 2). The correlation between ELISA results for the
training set and the independent test set was 95%, and
between the independent set tested by ELISA and the
training set tested by IPAS it was 87%. Elevated concen-
trations at 1 year from randomization compared to baseline
were observed in these independent samples for all ten
proteins studied.
Discussion
The objective of this proteomic study was to determine
whether an in-depth, unbiased, quantitative analysis of
serum proteins in a clinical trial setting would uncover
changes that are relevant to the objectives of the clinical
trial, thereby supporting the utility of comprehensive
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Table 3
Significant GeneGo biological networks for proteins that met a FDR <0.05
Network Network 
number Name P-value objects Objects in the network*
1 Blood coagulation 1.66 e-6 7/83 UP: F12, F9, F10, PROZ, SERPING1, MST1
DOWN: MMP2
2 Complement system 1.57 e-4 5/73 UP: SERPING1, C2 (C2a, C2b) 
DOWN: MBL2
3 Kallikrein-kinin system 2.84 e-4 7/183 UP: PLG, SERPING1, F9, F10, F12, HABP2
4 Cell adhesion, cell matrix interactions 6.34 e-4 7/209 UP: VTN, TGFBI, HABP2, LGALS3BP, LGALS1
DOWN: MMP2, COL1A1
5 Platelet-endothelium- 1.42 e-3 6/175 UP: PLG, F12, F10, SERPING1, VTN
leukocyte interactions DOWN: MMP2
6 Ossification 4.34 e-3 5/152 UP: INHBE, IGFBP4, IGFBP1-IGFBP6
DOWN: IGF1, TLL1
7 Cell proliferation 5.4 e-3 5/160 UP: IGFBP1, IGFBP4, IGFBP6
DOWN: IGF1, MMP2
8 Protein C signaling 6.05 e-3 4/103 UP: PLG, F9, F10
DOWN: EDG3
*UP and DOWN refer to up-regulated and down-regulated, respectively. C2, complement c2; LGALS3BP, galectin-3-binding protein; MBL2, mannose-
binding protein C; NOTCH, neurogenic locus notch homolog protein 2; TGFBI, transforming growth factor-beta-induced protein ig-h3.
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Table 4
Classification of proteins with statistically significant changes based on Gene Ontology
Protein Log2 ratio year one relative to baseline P-value
Blood coagulation and inflammation
Vitronectin (VTN) 0.374 9.27E-08
Ceruloplasmin (CP) [59] 0.789 1.51E-06
Plasminogen (PLG) [51] 0.307 1.50E-06
Kininogen (KNG1) [52] 0.265 2.89E-05
Coagulation factor XII (F12) [52] 0.364 4.64E-05
Coagulation factor IX (F9) 0.558 8.34E-05
Coagulation factor X (F10) 0.332 0.00029
Carboxypeptidase N, polypeptide 1 (CPN1) 0.288 0.0002
Platelet basic protein (PPBP) 0.273 0.00363
Tissue factor pathway inhibitor (TFPI) [51] -0.267 0.01152
Fibrinogen gamma chain (FGG) 0.273 0.01848
Matrix metalloproteinase 2 (MMP2) -0.681 0.03019
Protein Z, vitamin K-dependent plasma glycoprotein (PROZ) 0.676 0.03401
Hyaluronan-binding protein 2 (HABP2) 0.324 0.00029
Metabolism
Sex hormone binding globulin (SHBG) [68] 1.381 2.30E-07
Insulin-like growth factor binding protein 1 (IGFBP1) [18] 1.318 3.82E-05
Insulin-like growth factor binding protein 4 (IGFBP4) [18] 0.773 8.61E-06
Apolipoprotein A-II (APOA2) [57] 0.379 4.06E-06
Vitamin D binding protein (GC) [59] 0.298 5.82E-06
Apolipoprotein D (APOD) [57] -0.396 0.00133
Insulin-like growth factor binding protein 6 (IGFBP6) 0.303 0.00225
Insulin-like growth factor (IGF1) [18] -0.410 0.00366
Proprotein convertase subtilisin kexin 9 (PCSK9) 0.385 0.02486
Serpin peptidase inhibitor, clade A, member 6 (SERPINA6) 0.377 0.02446
Osteogenesis
Fetuin B (FETUB) 0.748 2.81E-07
Macrophage stimulating protein 1 (MST1) 0.546 0.00154
Collagen type 1, alpha 1 (COL1A1) -0.494 0.00023
Tolloid-like protein 1, bone morphogenetic protein 1 (TLL1) -1.150 0.0467
Neurogenic locus notch homolog protein 2 (NOTCH2) -0.289 0.01946
Neurogenic locus notch homolog protein 3 (NOTCH3) -0.622 0.02133
Fetuin A (AHSG) [59] 0.281 1.16E-06
Cell growth
Inhibin, beta E (INHBE) 0.472 0.01866
Follistatin-like 3 (FSTL3) -0.353 0.02042
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) 0.322 0.0036
Complement and immune response
Serpin peptidase inhibitor, clade G, member 1 (SERPING1) 0.551 0.01216
Complement C2 (C2) 0.333 0.00215
Complement factor H-related protein 5 (CFHL5) 0.294 6.72E-05
Complement factor B (BF) 0.271 1.06E-06
Pantetheinase (VNN1) 0.564 0.00079
Leucine-rich alpha-2-glycoprotein (LRG1) 0.539 0.00031
Neutrophil defensin 1 (DEFA1) 0.303 0.00683
Mannose-binding protein C (MBL2) -0.300 0.00094
TRAF-type zinc finger domain-containing protein 1 (TRAFD1) -3.863 0.00762
Lactotransferrin (LTF) [69] 0.285 0.04264
Trefoil factor 3 (TFF3) 1.936 0.00019
Vessel morphogenesis
Autotaxin (ENPP2) 0.581 0.00395
Vasorin (SLITL2) -0.383 0.01997
Transgelin 2 (TAGLN2) -0.542 0.01725
Endothelial differentiation G-protein coupled receptor 3 (EDG3) -2.998 0.00033
Cardiomyopathy associated protein 5 (CMYA5) -4.1374 0.01562
Continued overleaf
profiling of the serum proteome for clinical investigations.
The choice of clinical trial for this study, namely the WHI
CEE randomized controlled trial, is significant from the
point of view of health effects observed, which include an
adverse effect on stroke and venous thromboembolism and a
reduction of hip fractures. Additionally, given that some
findings have been published with respect to the effect of
CEE on a selected set of serum proteins, there was an oppor-
tunity to assess concordance of proteomics-derived data
with previously observed findings and to assess the potential
of proteomics to uncover novel protein changes related to
oral ET. We used acrylamide isotopic labeling of cysteine
residues to obtain quantitative data for changes in serum
proteins between baseline and 1 year after CEE for 50
subjects. This labeling approach is chemically very efficient
as shown by the lack of unlabeled cysteines in searched mass
spectra [19]. It would be expected given the number of
proteins quantified that approximately 31 proteins would
satisfy a nominal P < 0.05 selection criterion under a global
null hypothesis. The number of quantified proteins that
reached this threshold of statistical significance was 116,
which represented a sizeable fraction (19%) of the proteins
with quantitative measures and is indicative of a substantial
effect of CEE on the serum proteome, based on a systematic,
unbiased analysis.
It was of interest to determine the contribution of EREs to
upregulation of protein levels with oral ET. The genes for
four up-regulated proteins contained conserved EREs. LTF
is a well known estrogen-regulated gene [37-40]. As with all
classical estrogen target genes, the human and mouse
orthologs of LTF both contain an ERE at a similar location in
their promoter region, and are most sensitive to estrogen
stimulation in the reproductive organs [39,40].The human
AGT gene includes an ERE close to the TATA box in its
promoter region, which may be responsible for its increased
transactivation by estrogen [41]. The TFF3 gene, which plays
a role in mucosal protection and repair in the gastro-
intestinal tract, is known to be induced by estrogen [42], and
it is over-expressed in several types of cancer [43]. Elevated
serum levels of TFF3 have been reported in inflammatory
bowel disease [44] and ulceration of the upper gastro-
intestinal tract [45]. LGALS1 was shown to be induced by
estrogen [46]. One down-regulated protein (MMP2) had an
ERE in the downstream region of the gene. In one study,
estrogen was shown to increase MMP2 activity and protein
expression in human granulosa lutein cells [47]. In another
study, treatment with low dose estrogens increased MMP2
expression and activity. However, estrogens at a similar level
as in the case of women receiving hormone replacement
therapy failed to up-regulate MMP2 expression and activity
[48]. The human MMP2 promoter contains several potential
cis-acting regulatory elements, including cAMP response
element-binding protein (CREB), AP-1, PEA3, C/EBP, P53,
Est-1, AP-2, and Sp1 binding sites [49,50]. This may suggest
that regulation of MMP2 gene expression is not primarily
through the classic ERE-mediated pathway [1]. Given that
most up-regulated proteins with oral ET do not display a
conserved ERE in their corresponding genes, it would follow
that their upregulation is likely through other mechanisms.
Up-regulated serum levels were observed for as many as
nine proteins that play a role in coagulation (PLG, F9, F10,
factor XII (F12), KNG1, PROZ, SERPING1 (serpin peptidase
inhibitor, clade G, member 1), VTN, and FGG (fibrinogen
gamma chain)), which may be relevant to the increased risk
of venous thromboembolism and stroke with CEE. Of these,
PLG [51], FGG, F12, and high molecular weight KNG1 [52]
have been reported to increase with ET. The last three of
these are components of the plasma kallikrein-kinin system,
which mediates changes in coagulation, inflammation and
blood pressure, all of which may contribute to athero-
thrombosis. Increased levels of PROZ, F9, F10, VTN, FGG,
and platelet basic protein (PPBP) are novel findings. PROZ
is structurally related to F9 and F10, and serves as a cofactor
for the inactivation of activated F10. A case-control study
http://genomemedicine.com/content/1/4/47 Genome Medicine 2009, Volume 1, Issue 4, Article 47 Katayama et al. 47.10
Genome Medicine 2009, 1:47
Table 4 (continued)
Protein Log2 ratio year one relative to baseline P-value
Other
Angiotensinogen (AGT) [15,16] 1.148 7.16E-10
Cathepsin S (CTSS) 0.588 0.04665
Galectin-3-binding protein (LGALS3BP) 0.416 0.00214
Galectin 1 (LGALS1) 0.305 0.02924
E3 ubiquitin-protein ligase UBR1 (UBR1) -0.422 0.00511
Tropomyosin alpha-4 chain (TPM4) -1.258 0.0269
DNA helicase B (HELB) -1.862 0.02157
Putative Polycomb group protein ASXL1 (ASXL1) -2.658 0.02290
Protein CREG2 (CREG2)
Protein RIC1 homolog (KIAA1432) -4.153 0.00155
Protein FAM59B (FAM59B) -2.755 0.00119
KH homology domain-containing protein 1 (C6orf148) -3.060 0.00116
Alpha-1B-glycoprotein (A1BG) 0.331 1.82E-06
Disks large homolog 2 (DLG2) 1.749 0.04913
Proteins with prior associations with ET are indicated with numbered references.
found a strong, independent relationship between elevated
blood levels of PROZ and ischemic stroke during the acute
phase [53]. Thus, our results are consistent with the notion
that PROZ might be an important factor in the pathogenesis
of ischemic stroke in postmenopausal women receiving CEE.
Vascular smooth muscle cells constitutively elaborate the
zymogen form of MMP2. When activated, MMP2 promotes
vascular lesion development [54].
Our data indicate that IGF1/IGFBP levels were significantly
changed after 1 year of CEE, in accordance with data from a
small randomized study of 35 healthy postmenopausal
women in which circulating IGF1 levels were significantly
reduced by CEE and plasma concentrations of IGFBP1 and
IGFBP4 increased from baseline [18]. We confirmed in this
larger study that CEE increased the IGFBP1 and IGFBP4
serum levels from baseline to 1 year of ET and decreased IGF1.
We observed for the first time CEE related increased levels
of proprotein convertase subtilisin kexin 9 (PCSK9), which
regulates low-density lipoprotein receptor levels. Mutations
in the PCSK9 gene have been associated with CHD risk
[55,56]. Our data confirm previously reported high levels of
APOA2, a major component of high-density lipoprotein,
with CEE [57]. We also found that SERPINA6 (serpin pep-
tidase inhibitor, clade A, member 6), the major transporter
for glucorticoids and progestins in the blood, is elevated
after CEE. It has been negatively correlated with insulin
resistance and body mass index [58]. Conversely, increased
blood levels of GC [59] with CEE are associated with obesity
and insulin resistance [60]. Thus, through several pathways,
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Figure 3
Mean ratios (95% confidence intervals (CI)) for MS-based (IPAS, shown in red) and ELISA-based quantification (shown in black for the same set of 50 sera
analyzed by MS and in blue for the independent set of 50 sera). SHBG ELISA data were based on a separate independent set of sera.
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estrogen appears to have effects on cardiovascular risk
characteristics.
We found that several proteins from the inflammation, innate
immunity and complement cascade were elevated after CEE,
suggestive of a low grade inflammatory state, consistent with
previously reported CEE-induced increases in C-reactive
protein [14]. Some proteins implicated in cellular growth
had increased levels with CEE (LTF, inhibin, beta E (INHBE),
IGFBPs) whereas others were decreased (follistatin-like 3
(FSTL3), IGF1). Interestingly, we found changes in five
proteins (AHSG, fetuin B (FETUB), macrophage stimulating
protein 1 (MST1), collagen type 1, alpha 1 (COL1A), tolloid-
like protein 1, bone morphogenetic protein 1 (TLL1)) directly
implicated in osteogenesis and several others (IGF/IGFBPs,
MMP2, NOTCH-1 and 3) that play a role in osteogenesis.
These findings are of interest given the reduction in
fractures with CEE.
AGT, a potent blood pressure vasoconstrictor, occurred at
increased levels following CEE as previously observed
[15,16]. Increases in levels of proteins from the plasma
kallikrein-kinin system also suggest an impact of CEE on
blood pressure regulation, although this has not been borne
out in blood pressure measurements of women taking CEE.
Changes in levels of several proteins implicated in blood vessel
morphogenesis and angiogenesis were observed. Autotaxin
(ENPP2), an angiogenic factor and stimulant for cellular
growth, was found to be increased whereas other proteins
(transgelin 2 (TAGLN2), endothelial differentiation G-protein
coupled receptor 3 (EDG3), cardiomyopathy associated
protein 5 (CMYA5)) were decreased. MMP2, which promotes
vascular lesion development [54], is decreased, as is SLITL2
(vasorin), which contributes to neointimal formation after
arterial injury [61]. Changes in these proteins may have an
effect on vasculature within 1 year of CEE.
Our proteomics study also confirmed that levels of lipo-
protein APOA2, which is CHD protective, are up-regulated,
while levels of APOD are down-regulated and apolipoprotein
A (LPA) not changed, in accordance with previous findings
from the WHI study [51]. The plasma kallikrein-kinin
system has been implicated in cardiovascular disease in
men, but activation of this system has not been specifically
investigated in individuals at risk for CHD [62].
Reduction of hip fractures is a well known effect of CEE and,
interestingly, we found that ossification was a major signifi-
cant affected network. Changes in five proteins (AHSG,
FETUB, MST1, COL1A, TLL1) directly implicated in osteo-
genesis were observed and several others (IGF/IGFBPs,
MMP2, NOTCH-1) that play a role in osteogenesis exhibited
altered levels with CEE.
To further support our proteomics findings, we measured by
ELISA a subset of deregulated proteins using the same sera
in our training set and in an additional validation set of 50
women. Our data showed a strong correlation between
ELISA and MS results in both test and validation sets,
reflecting reliability of MS and isotopic labeling for protein
quantification. For the three proteins where ELISA
measurements did not confirm the IPAS ratios, it is difficult
to precisely determine the cause of the discrepancies. It is
possible that different species are measured by ELISA versus
IPAS (that is, different isoforms). Since the epitopes of the
antibodies used in ELISAs are often not specified or
ambiguous, it is difficult to conclusively determine if this is
the case.
The findings presented here relate specifically to the effect
on the serum proteome of orally administered postmeno-
pausal ET. It is well know that the effect of estrogen depends
on the route of administration [63,64]. For example, in one
study, IGF-1 concentrations were found to decrease
significantly with oral estrogen, whereas no significant
change was observed with transdermal estrogen at 6 months
[63]. Given the oral route of administration of estrogen in
our study, it was of interest to determine the organ source of
affected proteins. A search of gene expression data in
SymAtlas [65] indicated that approximately half of the 62
proteins that were dysregulated with oral CEE in our study
had the liver as their major organ source.
Protein changes after oral ET in postmenopausal women
observed in this study indicate a substantial effect on
http://genomemedicine.com/content/1/4/47 Genome Medicine 2009, Volume 1, Issue 4, Article 47 Katayama et al. 47.12
Genome Medicine 2009, 1:47
Figure 4
Comparison of mean ratios (1 year ET/baseline) by IPAS MS and by ELISA.
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coagulation and metabolic proteins that may explain the
increased risk of venous thromboembolism and stroke and
the reduced risk of fracture found in the WHI trial.
Contributions of the route of administration of estrogen
(oral versus transdermal) and dosage to effects on the serum
proteome require further study, and our findings may not be
directly relevant to parenteral routes of delivery or lower
doses. We note that transdermal estrogen has not been
linked to an increased risk of venous thromboembolism in a
recent large meta-analysis [66].
Conclusions
In-depth proteomic MS analysis of plasmas obtained from
subjects in the WHI hormone replacement therapy trial
uncovered 116 proteins (19%) that exhibited quantitative
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Figure 5
Dynamic range of IPAS MS pointing to proteins validated by ELISA. (a) Correlation between spectral counts (number of tandem mass spectra (MS2)
acquired per protein) and estimated/measured serum concentrations. (b) Cumulative protein identifications are plotted versus ELISA protein
concentration determined by ELISA measurments (red) and estimated concentration (blue) as determined by spectral counts.
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changes 1 year after CEE. Protein changes were related to
processes that included coagulation, metabolism, osteo-
genesis, inflammation, and blood pressure maintenance.
Findings for selected proteins were confirmed in the initial
set of plasmas using ELISA, and further validated in an
independent set of samples. This in-depth proteomic study
has shown that a substantial fraction of the serum proteome
is affected by CEE. The observed changes have relevance to
findings from the clinical trial. This study points to the
potential for proteomic investigations to provide a quanti-
tative assessment of changes in the proteome that could
elucidate effects of various interventions as part of clinical
trials, and that form the basis of further investigations.
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